Novo Nordisk A/S rose the most in a month after its diabetes blockbuster Ozempic beat Eli Lilly & Co.’s older drug Trulicity ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Wegovy has been a hugely popular treatment since the Food and Drug Administration (FDA) approved it for weight loss in ...

In a study with people with Type 2 diabetes and cardiovascular disease, the drug Ozempic was shown to reduce the risk of ...

A senior Novo Nordisk executive on Wednesday described the drugmaker's ongoing trial of its blockbuster obesity medicine for ...

Letters from the FDA targeted over 100 companies, saying multiple drug firms are pushing “false or misleading” claims about ...

In a new study, Ozempic-maker Novo Nordisk shows that its weight loss pill could achieve the similar efficacy as injectables.

Rybelsus is approved to treat type 2 diabetes but can now officially list its heart benefits as well.

Novo Nordisk has a strong financial position and portfolio of weight-loss and diabetes treatments. See why NVO’s stock dip ...

Novo Nordisk (NVO) shares rose 6% premarket on Thursday after a real-world study showed its diabetes drug Ozempic ...

Canadians now have a comprehensive, convenient home delivery option for Ozempic® and Wegovy® prescriptions MISSISSAUGA, ON, ...

Ozempic® (once-weekly injectable semaglutide) was associated with a 23% reduced risk of heart attack, stroke and death in ...